STAT+: Gilead’s Trodelvy fails in lung cancer and raises new questions on antibody drug conjugate drugs

Gilead said Trodelvy, its medicine that combines an antibody with chemotherapy, did not significantly extend the lives of patients with non-small cell lung cancer when given after a first treatment…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks